NDT Pharmaceuticals Inc (NDTP)

[drugmanrx]

Dot connecting

Shareholder meeting letter

- name change of the company to Compelling Competitive Advantage or some other name as determine by the director

- contract that CCA has with University or Pennsylvania will be transfers to MILV

per 2016 SEC document that contract

CCA and the University of Pennsylvania ("PENN") and the Children's Hospital of Philadelphia ("Children's Hospital") are engaged in a co-development alliance which is combining CCA's NPC technology with other PENN and Children's Hospital technologies to co-develop technologies to be jointly owned by CCA, PENN and Children's Hospital, including compounds to treat, and to a certain extent, prevent traumatic brain injury. This alliance also entails development involving dendrites, neurodevelopment, bone morphogenetic proteins, glutamate excitotoxicity, neural regeneration, injury-induced altered brain excitability, circuit rearrangement and synaptic function, including the development of pharmaceuticals."

Per public filings a patent assigned to CCA for drug delivery using nano particle for the purpose of crossing the blood brain barrier.

Methods of Making and Using Nano Scale Particles
Publication number: 20160317452
Abstract: A method for preparing a phospholipid delivery system encapsulating one or more bio-affecting compounds, includes the steps of solubilizing a heterogeneous phospholipid mixture into an organic solvent to form a concentrated formulation of phospholipids, in which the phospholipids include a charged phospholipid species and mixing the concentrated formulation with an aqueous solution having at least one bio-affecting compound. A method of using a phospholipid delivery system encapsulating at least one bio-affecting compound for the administration to an individual in need thereof is also disclosed.
Type: Application
Filed: June 13, 2016
Publication date: November 3, 2016
Applicant: COMPELLING COMPETITIVE ADVANTAGE, LLC
Inventor: Michael W. Fountain

University of Pennsylvania Brain trauma research

Penn Center for Brain Injury and Repair

The Penn Center for Brain Injury and Repair (CBIR) is one of only five programs nationwide designated by the National Institutes of Health as a Brain Injury Center.

https://www.med.upenn.edu/cbir/

CBIR is a multi-disciplined network of more than 25 principal investigators and their teams representing the diverse areas of expertise critical to the research, assessment, diagnosis and treatment of Traumatic Brain Injury (TBI). For over 30 years, CBIR has coordinated the science and practice of Neurosurgery, Bioengineering, Pharmacology, Pathology, Neurology, Pediatrics, Neuroradiology, Rehabilitation, and Emergency Medicine in order to improve all aspects of TBI patient care and outcomes. The CBIR cooperative constitutes one of the strongest, most integrated research teams in the world working together to discover, document and implement ways to significantly improve the quality of life for people suffering from TBI and to prevent the "secondary" or delayed injuries that are initiated by brain trauma.

Lawrence Kubin, director of Compelling Competitive Advantage LLC and former NFL linebacker.

"Mr. Kubin is assisting CCA with product development focusing on traumatic brain injury."